In a report released on March 9, Matthew Henderson from J.P. Morgan maintained a Sell rating on Otsuka (OSUKF – Research Report), with a price ...

Japan's Otsuka Pharma has agreed to take control of US biotech Jnana Therapeutics in a deal that will give it rights to a clinical-stage candidate for the rare metabolic disorder phenylketonuria ...

Otsuka Pharma and Click Therapeutics' Rejoyn (formerly CT-152) app – which is used to help people with MDD manage their emotions more effectively – can be unlocked with a prescription from a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Caliber recently launched 4 digital solutions that further strengthen its portfolio and also position the company at the ...

Acer Inc. (TWSE: 2353) announced its financial results for the fourth quarter of 2024 and fiscal 2024 ended December 31. In the fourth quarter, Acer reported consolidated revenues of NT$66.02 billion, ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...

He has received honorariums from Bial Pharma, Eli Lilly, Otsuka, and Sumitomo. Provenance and peer review: Not commissioned, not externally peer reviewed.